Abstract: A light emitting display device includes a first display area; and a second display area disposed adjacent to the first display area, wherein the second display area includes a pixel driving part, a main light-emitting element directly connected to the pixel driving part, and an additional light-emitting element connected to the main light-emitting element, the additional light-emitting element overlaps a peripheral driving part in a plan view, the peripheral driving part generates a signal provided to the pixel driving part, the main light-emitting element and the additional light-emitting element each include a first electrode, an emission layer, and a second electrode, the pixel driving part is electrically connected to the second electrode of the main light-emitting element and the second electrode of the additional light-emitting element, and the second electrode of the additional light-emitting element and the second electrode of the main light-emitting element are separated by a separator.

Abstract: A light emitting display device includes a first display area; and a second display area disposed on an external side of the first display area, wherein the second display area includes a pixel driver, a main light emitting diode electrically connected to the pixel driver, and an additional light emitting diode electrically connected to the main light emitting diode, the additional light emitting diode overlaps a peripheral driver that generates signals provided to the pixel driver, the main light emitting diode and the additional light emitting diode each include a first electrode, an emission layer, and a second electrode, and the second electrode of the main light emitting diode is electrically connected to the first electrode of the additional light emitting diode.

Abstract: Disclosed is an ionomer for a high-temperature polymer electrolyte membrane fuel cell, which includes a phosphorus (P)-containing functional group having proton conductivity and partially contains fluorine in the main chain thereof.

Abstract: The present disclosure relates to a novel PLK1 degradation inducing compound having a structure according to Formula I, a method for preparing the same, and the use thereof. The compounds of the present disclosure exhibit an effect of inducing PLK1 degradation. Therefore, the compounds of the present disclosure may be effectively utilized for preventing or treating PLK1-related diseases.

Abstract: A display device includes: a substrate; a transistor disposed on the substrate; a first electrode disposed on the substrate; a pixel definition layer disposed on the first electrode; a separator pattern layer disposed on the pixel definition layer; a second electrode disposed on the first electrode, the pixel definition layer, and the separator pattern layer; a connection layer connected between the transistor and the second electrode; an emission layer disposed between the first electrode and the second electrode; a conductive pattern layer; and a capping member covering a side end portion of the conductive pattern layer, wherein the conductive pattern layer and the connection layer are disposed on a same layer, and a part of the second electrode disposed on the separator pattern layer and a part of the second electrode disposed around the separator pattern layer are separated from each other.

Abstract: Disclosed are a display device and a method for manufacturing the same. The display device according to an embodiment includes a transistor that is disposed on a substrate, a first electrode that is disposed on the substrate, a pixel defining layer that is disposed on the first electrode, a separator pattern that is disposed on the pixel defining layer, auxiliary wiring that is disposed between the pixel defining layer and the separator pattern, a second electrode that is disposed on the first electrode, the pixel defining layer, and the separator pattern, connection wiring that connects the transistor to the second electrode, and an intermediate layer that is disposed between the first electrode and the second electrode. A portion of the second electrode disposed on the separator pattern and a portion of the second electrode disposed around the separator pattern are separated from each other.

Abstract: The present disclosure relates to a novel PLK1 degradation inducing compound having a structure according to Formula I, a method for preparing the same, and the use thereof. The compounds of the present disclosure exhibit an effect of inducing PLK1 degradation. Therefore, the compounds of the present disclosure may be effectively utilized for preventing or treating PLK1-related diseases.

Abstract: The present invention relates to a pharmaceutical composition for preventing, ameliorating, or treating cancer. More specifically, the present invention relates to a pharmaceutical composition for preventing or treating cancer including a lignan compound having a specific chemical structure (Chemical Formula 1); a health functional food composition for preventing or ameliorating cancer including the lignan compound; and a method for preventing, ameliorating, or treating cancer using the composition. Further, the present invention relates to a use of the lignan compound in the preparation of a pharmaceutical composition or a health functional food composition for preventing, ameliorating, or treating cancer.

Abstract: The present invention relates to a pharmaceutical composition for preventing, ameliorating, or treating cancer. More specifically, the present invention relates to a pharmaceutical composition for preventing or treating cancer including a lignan compound having a specific chemical structure (Chemical Formula 1); a health functional food composition for preventing or ameliorating cancer including the lignan compound; and a method for preventing, ameliorating, or treating cancer using the composition. Further, the present invention relates to a use of the lignan compound in the preparation of a pharmaceutical composition or a health functional food composition for preventing, ameliorating, or treating cancer.

Abstract: The present invention relates to a cosmetic composition for skin whitening comprising a small molecule-peptide conjugate. More specifically, it concerns the cosmetic composition for skin whitening comprising Caffeic acid-LG-NH2 or Coumaric acid-LG-NH2 as an active ingredient, which inhibits tyrosinase activity and melanin production, thereby showing an excellent skin whitening effect, and having no side effects to the skin by using a peptide component.

Abstract: The present invention relates to controlled and sustained release pharmaceutical composition and processes for preparing the same. The present invention is to provide processes to prepare an injectable sustained release pharmaceutical composition comprising a step to prepare biodegradable porous microspheres having accessible ionic functional groups, a step to incorporate a biopharmaceutical into the microspheres through ionic interaction by suspending or equilibrating the microspheres in a solution containing the biopharmaceutical and a step to recover and freeze-dry the biopharmaceutical-incorporated microspheres.

Abstract: Novel pyridyl imidazole derivatives of formula(I) inhibit effectively the action of angiotensin II and have a superior antihypertensive activity: ##STR1## wherein: A is a straight, branched or cyclic C.sub.1 -C.sub.6 alkyl or alkenyl group, OR.sup.1 (wherein R.sup.1 is a hydrogen, or a straight, branched or cyclic C.sub.1 -C.sub.6 alkyl or alkenyl radical), or NR.sup.2 R.sup.3 (wherein R.sup.2 and R.sup.3 are independently a hydrogen, or a straight, branched or cyclic C.sub.1 -C.sub.6 alkyl radical);B is a group of the following formula ##STR2## D is a hydrogen; a halogen; a straight, branched or cyclic C.sub.1 -C.sub.6 alkyl, C.sub.2 -C.sub.6 alkenyl or C.sub.2 -C.sub.6 alkynyl group which is optionally substituted with OH, a C.sub.1 -C.sub.4 alkoxy radical, CO.sub.2 R.sup.1, COR.sup.1, CON(R.sup.1).sub.2 or N(R.sup.1).sub.2, wherein R.sup.1 is the same as defined above; tetrazol-5-yl; a perfluoro-C.sub.1 -C.sub.4 alkyl group; or N(R.sup.1).sub.2, OR.sup.1, CO.sub.2 R.sup.1 or CON(R.sup.1).sub.2, wherein R.

Abstract: Novel imidazole derivatives of formula(I) inhibit effectively the action of angiotensin II and have a superior antihypertensive activity: ##STR1## wherein: A is a straight, branched or cyclic C.sub.1 -C.sub.6 alkyl group, or OR.sub.1 wherein R.sub.1 is a hydrogen, or a straight, branched or cyclic C.sub.1 -C.sub.6 alkyl radical; B is a halogen, CF.sub.3 or CF.sub.2 CF.sub.3 ; X is N or N-oxide; Y is --CH.sub.2 --, --CH(OR.sub.1)-- wherein R.sub.1 is the same as defined above, or --C(.dbd.O)--; n is 0 or an integer of 1 to 4; Z is a halogen, --OH, --OR.sub.1, --NR.sub.1 R.sub.2, --N(.dbd.O)R.sub.3 R.sub.4, --C(.dbd.O)R.sub.1, --C(.dbd.O)OR.sub.1, --CH(OR.sub.1).sub.2 or --C(.dbd.O)N.sub.1 N.sub.2 wherein R.sub.1 is the same as defined above, R.sub.2 is, independently of R.sub.1, a hydrogen, or a straight, branched or cyclic C.sub.1 -C.sub.6 alkyl radical, and R.sub.3 and R.sub.4 are independently a straight, branched or cyclic C.sub.1 -C.sub.